Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell TransplantationNirali N. Shah, Guenther Koehne, Divya Koura et al.|Blood|2023Cited by 12
Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell TransplantationNirali N. Shah, Guenther Koehne, Jacques Azzi et al.|Transplantation and Cellular Therapy|2024Cited by 2